KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

Completed · Phase 2

Conditions studied: Stiff-Person Syndrome, SPS

In brief

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome

Key facts

Study ID

NCT06588491

Run by

Kyverna Therapeutics

People needed

27

Starts

2024-09-25

Expected to finish

2026-06-25

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.